Compare MSAI & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MSAI | INAB |
|---|---|---|
| Founded | 1995 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.8M | 22.9M |
| IPO Year | N/A | 2020 |
| Metric | MSAI | INAB |
|---|---|---|
| Price | $0.35 | $1.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $2.75 | ★ $180.00 |
| AVG Volume (30 Days) | ★ 597.0K | 31.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $106.56 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.25 | $0.12 |
| 52 Week High | $2.40 | $4.20 |
| Indicator | MSAI | INAB |
|---|---|---|
| Relative Strength Index (RSI) | 62.19 | 53.00 |
| Support Level | $0.27 | $1.52 |
| Resistance Level | $0.39 | $2.15 |
| Average True Range (ATR) | 0.03 | 0.14 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 77.55 | 67.59 |
MultiSensor AI Holdings Inc build and deploy intelligent multi-sensing platforms incorporating edge and cloud software solutions that leverage artificial intelligence (AI). It is a provider of sensing systems built around high-resolution thermal imagers, visible and acoustic imagers, as well as vibration and laser spectroscopy sensors, that perceive and measure heat, sound, vibration, and gas in industrial assets and the surrounding environment, helping companies gain insight to protect and manage their most important assets and infrastructure. It also offers a wide range of form factors for its sensor devices, including, among other form factors, small to large handheld designs with built-in displays and controls, and fixed-mounted single- and multi-sensor camera sensor systems.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.